Ligand, Travere Therapeutics receives full FDA approval for Filspari

Ligand (LGND) announced that its partner Travere Therapeutics (TVTX) has received full approval from the FDA for Filspari to slow kidney function decline in adults with primary IgAN who are at risk of disease progression. Ligand is entitled to milestone payments and a 9% royalty on worldwide net sales of Filspari. Filspari was granted accelerated approval in February 2023 based on the surrogate marker of proteinuria. Full approval is based on long-term confirmatory results from the PROTECT Study demonstrating that Filspari significantly slowed kidney function decline over two years compared to irbesartan.